Bombardier Announces Closing of Placement of 7.45% Notes Due 2034 and Announces Amendment and Extension of Certain Consent Solicitations
MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) (the “Corporation”) today announced that it has completed the issuance and sale to an institutional accredited investor (the “Investor”) of US$260,000,000 aggregate principal amount of Bombardier’s 7.45% Senior Notes due 2034 (the “Additional Notes”) at a purchase price of par. The Additional Notes are additional notes of the same series, and are on the same terms and conditions, as the 7.45% Senior Notes due 2034 (the “2034 Notes”) currently outstanding under the indenture, originally dated as of April 21, 2004, governing the 2034 Notes (the “2034 Indenture”). Following this private placement, the aggregate principal amount outstanding under the 2034 Notes is US$510,000,000. The Corporation intends to use the net proceeds from this private placement for the repayment of a portion of the Corporation’s outstanding indebtedness.
The Corporation also today announced that it has amended and supplemented the terms of the consent solicitations in respect of its 2034 Notes and its 7.35% Debentures due 2026 (“Canadian Notes”), as set forth in the Corporation’s Notice of Extension and Amendment dated May 18, 2021 (“Notice of Amendment”) to the Consent Solicitation Statement dated May 3, 2021 (as amended by the press releases dated May 12, 2021 and May 14, 2021, the “Consent Solicitation Statement” and, together with the Notice of Amendment, the “Supplemental Consent Solicitation Statement”).
In respect of the 2034 Notes, the Consent Solicitation (as defined in the Supplemental Consent Solicitation Statement) has been amended and supplemented in order to (i) remove the record date for participation in the 2034 Notes Consent Solicitation and (ii) extend the expiration date of the 2034 Notes Consent Solicitation to 5:00 p.m., New York City time, on May 21, 2021 (the “Extended Expiration Date”).
The Company has obtained the Investor’s consent in respect of the proposed amendments to the 2034 Indenture described in the Consent Solicitation Statement. The Investor, which is the beneficial owner of a majority of the principal amount of the 2034 Notes, has further agreed to give its affirmative consent in the 2034 Notes Consent Solicitation.
ALL CONSENTS PREVIOUSLY GIVEN IN THE CONSENT SOLICITATION WITH RESPECT TO THE 2034 NOTES ARE NO LONGER EFFECTIVE, AND ANY HOLDER OF 2034 NOTES WHO WISHES TO PROVIDE ITS CONSENT IN THIS CONSENT SOLICITATION MUST VALIDLY GIVE THEIR CONSENT ON OR AFTER MAY 18, 2021 AND ON OR PRIOR TO THE EXTENDED EXPIRATION DATE. For the avoidance of doubt, any holder of 2034 Notes who has previously consented to the Consent Solicitation with respect to the 2034 Notes must validly deliver their consent again in order to receive the Consent Payment (as defined in the Supplemental Consent Solicitation Statement). Consents may not be revoked once given, including during any extension of the Consent Solicitation period, except as provided in the Supplemental Consent Solicitation Statement.
Consent Solicitation in respect of the Canadian Notes has been extended such that the expiration date of the Consent Solicitation is the Extended Expiration Date (being 5:00 p.m., New York City time, on May 21, 2021).
All holders of the 2034 Notes or Canadian Notes whose consents are properly made and not revoked on or prior to the Extended Expiration Date will be entitled to receive the Consent Payment, subject to the terms and conditions set forth in the Supplemental Consent Solicitation Statement.
Except as set forth in the Supplemental Consent Solicitation Statement with respect to the removal of the record date in respect of the Consent Solicitation for the 2034 Notes and the extension of the expiration dates of the Consent Solicitations for the 2034 Notes and the Canadian Notes, the terms and conditions of the Consent Solicitations remain the same as set forth and described in the original Consent Solicitation Statement dated May 3, 2021 (as amended and extended). The Corporation reserves the absolute right, subject to applicable laws, to further amend, waive or modify the terms of the Consent Solicitations in any manner. For a complete statement of the terms and conditions of the Consent Solicitations, holders are encouraged to read the Supplemental Consent Solicitation Statement.
Holders are advised to check with any bank, securities broker or other intermediary through which they hold any of the notes as to when such intermediary needs to receive instructions from a holder in order for that holder to be able to participate in, or (in the circumstances in which revocation is permitted) revoke their instruction to participate in, the Consent Solicitations, before the deadlines specified herein and in the Supplemental Consent Solicitation Statement. The deadlines set by each clearing system for the submission and withdrawal of instructions will also be earlier than the relevant deadlines specified herein and in the Supplemental Consent Solicitation Statement.You should check with such broker, dealer, commercial bank, trust company or other nominee to determine whether they will charge you a fee for delivering your consent on your behalf.
For additional information regarding the terms of the Consent Solicitations, or to obtain additional copies of the Supplemental Consent Solicitation Statement, please contact Global Bondholder Services Corporation at (866) 807 2200 or by email at firstname.lastname@example.org, or, in respect of the Canadian Notes, Kingsdale Partners LP at 1-888-518-6824 or by email at email@example.com. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Consent Solicitations.
Citigroup Global Markets Inc. and UBS Securities LLC are acting as the Solicitation Agents for the Consent Solicitations. Questions concerning the terms of the Consent Solicitations should be directed to Citigroup Global Markets Inc. at (212) 723-6106 (collect) or (800) 558-3745 (toll-free) or UBS Securities LLC at (203) 719-4210 (collect) or (888) 719-4210 (toll-free).
None of the Corporation, the trustees for the notes, the agents under the respective indentures for the notes, the information agents, any of their respective subsidiaries or affiliates or any of its or their respective directors, officers, employees or representatives makes any recommendation to holders as to whether or not to deliver their consent pursuant to any of the Consent Solicitations, and none of the foregoing has authorized any person to make any such recommendation. Holders must decide whether to provide their consent.
This notice does not constitute or form part of any offer or invitation to purchase, or any solicitation of any offer to sell, the notes or any other securities in the United States or any other jurisdiction, and neither this notice nor any part of it, nor the fact of its release, shall form the basis of, or be relied on or in connection with, any contract therefor. The Consent Solicitations are made only by and pursuant to the terms and conditions of the Supplemental Consent Solicitation Statement and the information in this notice is qualified by reference to the Supplemental Consent Solicitation Statement.
This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy or sell any security and shall not constitute an offer, solicitation, sale or purchase of any securities in any jurisdiction in which such offering, solicitation, sale or purchase would be unlawful.
The securities mentioned herein have not been and will not be registered under the United States Securities Act of 1933, as amended, any state securities laws or the laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or in a transaction exempt from or not subject to such registration requirements. The securities mentioned herein have not been and will not be qualified for distribution to the public under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada must be made on a basis which is exempt from the prospectus requirements of such securities laws.
Holders are requested to read and consider carefully the information contained in the Supplemental Consent Solicitation Statement and to deliver their consent in accordance with the instructions set forth in the Supplemental Consent Solicitation Statement.
Bombardier is a global leader in aviation, creating innovative and game-changing planes. Our products and services provide world-class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.
Headquartered in Montréal, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of more than 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.
Bombardier is a trademark of Bombardier Inc. or its subsidiaries.
This announcement does not constitute an offer to buy or the solicitation of an offer to sell any securities in any jurisdiction or in any circumstances in which such offer or solicitation is unlawful. In those jurisdictions where the securities, blue sky or other laws require the Consent Solicitations to be made by a licensed broker or dealer, the Consent Solicitations will be deemed to be made by one or more registered brokers or dealers licensed under the laws of such jurisdiction.
Certain statements in this announcement are forward-looking statements based on current expectations. By their nature, forward-looking statements, including statements with respect to the Corporation’s ability to complete the Consent Solicitations, are based on estimates, projections, beliefs and assumptions that Bombardier believes are reasonable but are not guarantees of future events and results.
Forward-looking statements require us to make assumptions and are subject to important known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from those set forth in the forward-looking statements. For additional information regarding these risks and uncertainties, and the assumptions underlying the forward-looking statements, please refer to the Supplemental Consent Solicitation Statement.
|Francis Richer de La Flèche|
Vice President, Financial Planning
and Investor Relations
+514 855 5001 x13228
Senior Director, Communications
+514 855 7167
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Bavarian Nordic leverer vacciner til Englands beredskab i forbindelse med nye tilfælde af abekopper11.6.2021 19:12:35 CEST | pressemeddelelse
KØBENHAVN, Danmark, 11. juni 2021 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet for nylig er blevet anmodet af de engelske sundhedsmyndigheder, Public Health England (PHE) og Medicines and Health Products Regulatory Agency (MHRA), om at levere koppevaccinen IMVANEX® til vaccination i forbindelse med nye, udefrakommende tilfælde af abekopper i mennesker i England. To relaterede tilfælde er blevet bekræftet og er blevet indlagt på et hospital i Liverpool. Den ene er sandsynligvis blevet smittet i Afrika, hvorfra familien ankom et par dage inden sygdommen brød ud, mens den anden sandsynligvis er blevet smittet af det første tilfælde efter hjemkomsten. Abekopper er en sjælden, men alvorlig sygdom, der naturligt forekommer i det centrale og det vestlige Afrika. Sygdommen er beslægtet med den menneskelige koppesygdom, om end den er mindre alvorlig med en dødelighed, der er estimeret til at være fra 1-10% af tilfældene. IMVANEX (MVA-BN) er godkendt af Europa-Kommissionen til
Bavarian Nordic Assists Public Health England in Response to New Cases of Monkeypox11.6.2021 19:12:35 CEST | Press release
COPENHAGEN, Denmark, June 11, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox in the UK. Two related cases were confirmed and admitted to a hospital in Liverpool. One was most likely infected in Africa, where the family arrived from a few days before onset of disease, and a sibling case most likely infected on UK soil by the first case. Monkeypox is a rare, but serious disease, which is endemic in Central and West Africa. The disease is quite similar to human smallpox, although it is less severe with an estimated fatality rate of 1-10%. IMVANEX (MVA-BN) is approved by the European Commission for active immunization against smallpox but has also received approval for monkeypox by the U.S. Food and Drug Administration (FDA) and Health Canada, as the only vaccine approved for
Minister Eriksen Søreide, Deputy Minister Ryabkov, and Deputy Secretary Hicks to Keynote 2021 Carnegie International Nuclear Policy Conference11.6.2021 17:30:00 CEST | Press release
Senior officials, leaders, and experts in defense, security, and nuclear policy convene for a 3-day conference on the most-pressing challenges in nuclear arms control, nonproliferation, deterrence, and security WASHINGTON, June 11, 2021 (GLOBE NEWSWIRE) -- From June 22-24, 2021, the Carnegie Endowment for International Peace will host its biennial International Nuclear Policy Conference virtually, including keynote addresses from: Ine Eriksen Søreide, Minister of Foreign Affairs for NorwaySergey Ryabkov, Deputy Minister of Foreign Affairs of the Russian FederationKathleen Hicks, U.S. Deputy Secretary of Defense Other speakers include: Izumi Nakamitsu, UN-Secretary-General and High Representative for Disarmament Affairs; Bishop Garrison, Senior Advisor to the U.S. Secretary of Defense for Human Capital and Diversity, Equity and Inclusion; Harry Harris, former U.S. ambassador to the Republic of Korea; and Maleeha Lodhi, former UN Representative for Pakistan. The full conference agenda ca
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS11.6.2021 16:20:00 CEST | Press release
Bid procedure, 2021-06-18BondsSWEDEN I/L BOND: 3114. SE0013748258. 2030-06-01 SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01 Bid date2021-06-18Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3114: 250 mln SEK +/-150 mln SEK 3111: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3114: 250 mln SEK per bid 3111: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-06-22Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-06-11 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS11.6.2021 16:20:00 CEST | Press release
Bid procedure, 2021-06-16BillsSWEDISH T-BILL: SE0014808747. 2021-09-15 SWEDISH T-BILL: SE0015244405, 2021-12-15 SWEDISH T-BILL: SE0015659529, 2022-03-16 Bid date2021-06-16Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0014808747: 1000 mln SEK +/-500 mln SEK SE0015244405: 1000 mln SEK +/-500 mln SEK SE0015659529: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0014808747: 1000 mln SEK per bid SE0015244405: 1000 mln SEK per bid SE0015659529: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-06-18Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-06-11 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between t
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER11.6.2021 16:20:00 CEST | Press release
Bid procedure, 2021-06-16CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-12-16 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-06-04 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-06-16Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS11.6.2021 16:20:00 CEST | Press release
Bid procedure, 2021-06-17BondsSWEDBANK HYPOTEK AB: 192. SE0010133207. 2023-03-15 STADSHYPOTEK AB: 1588, SE0011063015, 2024-03-01 SWEDISH COVERED BOND: 151, SE0013486156, 2030-06-12 SKANDINAVISKA ENSKILDA: 581, SE0013102043, 2026-12-16 LANSFORSAKRINGAR HYPOTEK: 519, SE0012324341, 2026-09-16 DANSKE HYPOTEK AB: 2512, SE0013877214, 2025-12-17 NORDEA HYPOTEK AB: 5533, SE0010442731, 2023-09-20 Bid date2021-06-17Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)192: 800 mln SEK +/-400 mln SEK 1588: 2000 mln SEK +/-1000 mln SEK 151: 700 mln SEK +/-350 mln SEK 581: 700 mln SEK +/-350 mln SEK 519: 600 mln SEK +/-300 mln SEK 2512: 200 mln SEK +/-100 mln SEK 5533: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)192: 800 mln SEK per bid 1588: 2000 mln SEK per bid 151: 700 mln SEK per bid 581: 700 mln SEK per bid 519: 600 mln SEK per bid 2512: 200 mln SEK per bid 5533: 1000 mln SEK per bid Lowest permitted bid volume